Gene expression signature predictive of rapid response to imatinib mesylate in Gastrointestinal Stromal Tumor (GIST)

Gene expression profiling using oligonucleotide microarrays performed on tumor samples obtained before and after imatinib mesylate (IM) therapy. Rapid responding (to IM) samples were compared to non-responding/stable disease samples as measured by CT scan measurements to identify a gene signature that can predict rapid response to IM. 54 samples, 29 pre-treatment biopsy samples, 25 post-treatment/post-surgery tumor samples from Gastrointestinal Stromal Tumors

本研究采用寡核苷酸微阵列（oligonucleotide microarray）技术，对甲磺酸伊马替尼（imatinib mesylate，简称IM）治疗前后获取的肿瘤样本开展基因表达谱分析。以CT扫描评估结果为依据，将对IM治疗快速应答的样本与无应答/疾病稳定的样本进行对比，旨在筛选出可预测IM快速应答的基因特征（gene signature）。本次数据集共包含54份胃肠道间质瘤（Gastrointestinal Stromal Tumors）样本：其中29份为治疗前活检样本，25份为治疗或术后肿瘤样本。